Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Status:
Not yet recruiting
Trial end date:
2025-02-26
Target enrollment:
Participant gender:
Summary
While chimeric antigen receptor T-cell (CAR T-cell) therapy produces impressive response
rates in heavily pre-treated patients, early loss of response remains a barrier. One
potential mechanism of relapse is limited CAR T-cell persistence. Pre-clinical research shows
that PI3K inhibition represents an intriguing mechanism for increasing CAR T-cell persistence
that is easily reversible and CAR T-cell agnostic. The investigators hypothesize that PI3K
inhibition with duvelisib would be safe, may provide effective prophylaxis against cytokine
release syndrome (CRS), and may enhance the persistence and efficacy of CAR T-cells in the
treatment of hematologic malignancies.